Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

McAuley JR, Bailey KM, Ekambaram P, Klei LR, Kang H, Hu D, Freeman TJ, Concel VJ, Hubel NE, Lee JL, Klei HB, Cheng J, Sekar P, Bridwell RE, Covic L, Lucas PC, McAllister-Lucas LM.

Oncogene. 2019 Aug 16. doi: 10.1038/s41388-019-0958-4. [Epub ahead of print]


EWS-FLI1 low Ewing sarcoma cells demonstrate decreased susceptibility to T-cell-mediated tumor cell apoptosis.

Bailey KM, Julian CM, Klinghoffer AN, Bernard H, Lucas PC, McAllister-Lucas LM.

Oncotarget. 2019 May 21;10(36):3385-3399. doi: 10.18632/oncotarget.26939. eCollection 2019 May 21.


Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.

Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS.

Oncoimmunology. 2018 Oct 11;8(1):e1512455. doi: 10.1080/2162402X.2018.1512455. eCollection 2019.


CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis.

McAuley JR, Freeman TJ, Ekambaram P, Lucas PC, McAllister-Lucas LM.

Front Immunol. 2018 Aug 15;9:1887. doi: 10.3389/fimmu.2018.01887. eCollection 2018. Review.


Post-transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review.

Stanley K, Friehling E, Ranganathan S, Mazariegos G, McAllister-Lucas LM, Sindhi R.

Pediatr Transplant. 2018 Aug;22(5):e13211. doi: 10.1111/petr.13211. Epub 2018 May 10. Review.


The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.

Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC.

Cancer Res. 2018 Mar 1;78(5):1225-1240. doi: 10.1158/0008-5472.CAN-17-1089. Epub 2017 Dec 19.


MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.

Klei LR, Hu D, Panek R, Alfano DN, Bridwell RE, Bailey KM, Oravecz-Wilson KI, Concel VJ, Hess EM, Van Beek M, Delekta PC, Gu S, Watkins SC, Ting AT, Gough PJ, Foley KP, Bertin J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2016 Sep 27;17(1):221-232. doi: 10.1016/j.celrep.2016.08.080.


API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.

Rosebeck S, Lim MS, Elenitoba-Johnson KS, McAllister-Lucas LM, Lucas PC.

World J Biol Chem. 2016 Feb 26;7(1):128-37. doi: 10.4331/wjbc.v7.i1.128. Review.


Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.

Nie Z, Du MQ, McAllister-Lucas LM, Lucas PC, Bailey NG, Hogaboam CM, Lim MS, Elenitoba-Johnson KS.

Nat Commun. 2015 Jan 8;6:5908. doi: 10.1038/ncomms6908.


Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling.

Markó L, Henke N, Park JK, Spallek B, Qadri F, Balogh A, Apel IJ, Oravecz-Wilson KI, Choi M, Przybyl L, Binger KJ, Haase N, Wilck N, Heuser A, Fokuhl V, Ruland J, Lucas PC, McAllister-Lucas LM, Luft FC, Dechend R, Müller DN.

Hypertension. 2014 Nov;64(5):1032-9. doi: 10.1161/HYPERTENSIONAHA.114.03900. Epub 2014 Sep 2.


The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling.

Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM.

Oncogene. 2014 May 8;33(19):2520-30. doi: 10.1038/onc.2013.195. Epub 2013 Jun 17.


Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.

Bailey KM, Castle VP, Hummel JM, Piert M, Moyer J, McAllister-Lucas LM.

J Pediatr Hematol Oncol. 2012 Aug;34(6):480-3. doi: 10.1097/MPH.0b013e3182580d6e.


Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance.

Van Beek M, Oravecz-Wilson KI, Delekta PC, Gu S, Li X, Jin X, Apel IJ, Konkle KS, Feng Y, Teitelbaum DH, Ruland J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2012 May 31;1(5):444-52.


An unusual case of membranous nephropathy associated with an ovarian tumor.

Chen A, Vander Lugt M, McAllister-Lucas LM, Killen PD, Blatt NB.

Pediatr Nephrol. 2011 Dec;26(12):2249-51. doi: 10.1007/s00467-011-1994-7. Epub 2011 Sep 4.


MALT1 protease: a new therapeutic target in B lymphoma and beyond?

McAllister-Lucas LM, Baens M, Lucas PC.

Clin Cancer Res. 2011 Nov 1;17(21):6623-31. doi: 10.1158/1078-0432.CCR-11-0467. Epub 2011 Aug 25. Review.


From MALT lymphoma to the CBM signalosome: three decades of discovery.

Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM.

Cell Cycle. 2011 Aug 1;10(15):2485-96. Epub 2011 Aug 1. Review.


Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment.

Rosebeck S, Lucas PC, McAllister-Lucas LM.

Future Oncol. 2011 May;7(5):613-7. doi: 10.2217/fon.11.35. Review.


Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM.

Science. 2011 Jan 28;331(6016):468-72. doi: 10.1126/science.1198946. Erratum in: Science. 2011 Apr 22;332(6028):421.


Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome.

Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, Lucas PC.

J Biol Chem. 2010 Dec 31;285(53):41432-42. doi: 10.1074/jbc.M110.158949. Epub 2010 Nov 1.


The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.

McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J, Delekta PC, Van Beek M, Lucas PC.

J Biol Chem. 2010 Aug 20;285(34):25880-4. doi: 10.1074/jbc.C110.109421. Epub 2010 Jul 5.


Finally, MALT1 is a protease!

McAllister-Lucas LM, Lucas PC.

Nat Immunol. 2008 Mar;9(3):231-3. doi: 10.1038/ni0308-231. No abstract available.


A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment.

Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K, Jin X, Swenson J, McAllister-Lucas LM.

Oncogene. 2007 Aug 16;26(38):5643-54. Epub 2007 Mar 5.


CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.

McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW, Nuñez G, Lucas PC.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):139-44. Epub 2006 Nov 13.


NF-kappaB signaling in lymphocytes: a new cast of characters.

Lucas PC, McAllister-Lucas LM, Nunez G.

J Cell Sci. 2004 Jan 1;117(Pt 1):31-9. Review.


Thoracic neural crest tumors in Beckwith-Wiedemann syndrome.

Thornburg CD, Shulkin BL, Castle VP, McAllister-Lucas LM.

Med Pediatr Oncol. 2003 Nov;41(5):468-9. Review. No abstract available.


A requirement for CARMA1 in TCR-induced NF-kappa B activation.

Wang D, You Y, Case SM, McAllister-Lucas LM, Wang L, DiStefano PS, Nuñez G, Bertin J, Lin X.

Nat Immunol. 2002 Sep;3(9):830-5. Epub 2002 Aug 5.


Protein kinase C-associated kinase (PKK) mediates Bcl10-independent NF-kappa B activation induced by phorbol ester.

Muto A, Ruland J, McAllister-Lucas LM, Lucas PC, Yamaoka S, Chen FF, Lin A, Mak TW, Núñez G, Inohara N.

J Biol Chem. 2002 Aug 30;277(35):31871-6. Epub 2002 Jun 28.


NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells.

Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP, Opipari AW Jr.

J Biol Chem. 2001 Dec 28;276(52):48921-9. Epub 2001 Oct 25.


Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction.

McAllister-Lucas LM, Inohara N, Lucas PC, Ruland J, Benito A, Li Q, Chen S, Chen FF, Yamaoka S, Verma IM, Mak TW, Núñez G.

J Biol Chem. 2001 Aug 17;276(33):30589-97. Epub 2001 May 31.


Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway.

Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF, Yamaoka S, Seto M, Nunez G.

J Biol Chem. 2001 Jun 1;276(22):19012-9. Epub 2001 Mar 21.


Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase.

Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, Ferguson K.

Gene. 1998 Aug 17;216(1):139-47.


Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding.

Turko IV, Haik TL, McAllister-Lucas LM, Burns F, Francis SH, Corbin JD.

J Biol Chem. 1996 Sep 6;271(36):22240-4.


An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase.

McAllister-Lucas LM, Haik TL, Colbran JL, Sonnenburg WK, Seger D, Turko IV, Beavo JA, Francis SH, Corbin JD.

J Biol Chem. 1995 Dec 22;270(51):30671-9.


Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase.

Francis SH, Colbran JL, McAllister-Lucas LM, Corbin JD.

J Biol Chem. 1994 Sep 9;269(36):22477-80.


The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone.

McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, Seger D, Trong HL, Colbran JL, Thomas MK, Walsh KA, Francis SH, Corbin JD, et al.

J Biol Chem. 1993 Oct 25;268(30):22863-73.

Supplemental Content

Loading ...
Support Center